TERT and breast cancer: A combined DNA-based biomarker approach was also recently evaluated in a screening study conducted by Springer et al. where they assessed the performance of a multigene panel assay that includes the screening of TERT promoter mutations and regions of interest in ten other somatically mutated genes (UROSEEK) for detecting BC 0–18 months prior to clinical diagnosis in high-risk symptomatic patients.